OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Jill Wechsler is BioPharm International's Washington Editor, firstname.lastname@example.org.
FDA’s approval of Biogen’s treatment for Alzheimer’s disease has raised questions about the agency’s accelerated approval process.
The Biden administration supports a notable increase in funding for public health and research as a lead priority for the coming year.
Expanded interest in advanced drug manufacturing and continuous production methods calls for more flexible production systems and regulatory policies.
FDA recently published a final guidance for making post-approval manufacturing changes to drugs and biologics, the culmination of a long-running effort to facilitate improvements in medical product quality through the product life cycle.